I recall. They’re most likely to get an EUA, and we can speculate on what that will mean for the stock price all day long, but we’re up about 2 points today on only one million shares. I think an EUA gives this baby a 50 million volume day.. $50? $60? $70? $100?? $100 is only $5 billion market cap. The risk/reward play here is staggering.

How about raise their price target?

We’ve never left! Holding strong and buying every effin Dip.

This appears to be a huge over reaction. I suspect we flushed out plenty of weak retail investors - while the drop is VERY painful to watch, I’m glad I added more today. Remember what happened when the Russian vaccine was announced several months ago? Broader markets rallied and Covid therapeutics, like HGEN, got dumped. This is the same scenario, albeit a bit more powerful because it’s Pfizer and not a Russian state sponsored vaccine. The fact is, we have over 100k new infections per day in the US, over 60% of Americans have indicated that they will not take the vaccine, and we are better positioned today than ever before to receive OWS funding and an EUA!
Fairly confident that we’re back above $10 this week. Good luck to all.

No, I haven’t. Thanks for the heads up. Will do some homework this weekend.

I believe that basically means that the company cannot issue anymore stock in the next 90 days, but the investors that purchased stock in the 2 offerings are free to sell all of their shares.
As for CYDY, I believe Nader is delusional. He can predict triple digit stock prices til the sun dont shine, but was basically ignored by Nasdaq, all major investment banks, all major institutional investors, governmental organizations, and now his retail investor base have begun to throw in the towel.

Sure. I appreciate this board very much.
I don’t participate as often as I’d like, but I try and read every message. The due diligence is second to none, and I try and provide value when I can. Adding on every dip, because this has a better risk/reward then any biotech I’ve seen in years.

Venrock and other institutions are not under any lock up. The shares were acquired in 2 offerings:
1) PIPE transaction in June, which generated an effective registration statement in August that freed up all of those shares.
2) Secondary at $8.50 immediately prior to uplist, of which those shares were immediately tradable.

As part of the June financing, management agreed to a 180 day lock up (which I believe ends on December 2nd) . However, I cannot picture a situation where Cameron and Dale Chappell begin to off-load their holdings in any substantial way that would put pressure on the stock. If they do, we have bigger problems to worry about!

I’m happy with that timeline, as I believe we should see phase 3 data by then, and there will be enough demand for our shares that Cameron and Dale taking some rightfully earned profits off the table really won’t budge the stock one bit.

One of my brokers told me. It apparently is on Bloomberg, but I can’t find anything either. Anyone here have access to a Bloomberg terminal to confirm?

Cantor Fitzgerald initiates coverage with a $25 target.

Management signed a 180 day lock-up as part of the June PIPE. I believe that ends December 2nd, though I can’t see management selling prior to an EUA. All shares from the PIPE and the offering in September are free trading now.

Pretty sure that’s Scooter. He hasn’t been around here for a few days.

I agree, Jay. I believe this is a special company on the cusp of unimaginable things. Novovax is a comp that comes to mind. I believe Noble, while still in active litigation against Humanigen, introduced over 60 retail investors to this story, who in turn told their friends and so on and so forth. I only know about HGEN through
my Noble broker, whom I know has told his friends and family about the company, as have I. Everything happens for a reason. Any entry point below $10 almost feels like free money. Good luck to us all.

Thank you. Ultimately, the fast money is getting out faster than new investors can replace them. It all boils down to data. If our phase 3 or BET trial have positive results, none of these daily gyrations matter, because we’re a $50 stock. One won’t remember whether they paid $3 or $5 or $7 at that point. If you did your research and have a firm belief that the science behind this works, then consider this a gift. The last 2 days have been painful to watch, but nothing has changed fundamentally, so I hope we’ve bottomed out and today’s prices are considered a gift!

PIPE shares are now free trading. There was no requirement for them to hold until NASDAQ uplist.
Venrock and Valient set the terms here. They don’t lose money. This deal was bulletproof from the onset.

Because they were up 6x. Why not begin liquidating now? Historically, stocks go down immediately after an uplist. Someone here did the research recently. Also, I don’t think any of the PIPE investors are getting out entirely, but the institutions have a fiduciary duty to their investors to NOT lose any money, and so I would think they need to recoup their cost basis as quickly as possible. Short sellers know this, so we’re likely shorting it as soon as the registration was declared effective, thereby accelerating the subsequent PIPE sales.

The prospectus from 8/10 was just a supplement to the one from 8/5, adding some information on Brazil trials and updated timelines on certain milestones.

I haven’t been wrong, and I have been lurking on iHub for years but didn’t create an account until it got personal. That’s all. Bottom line, I have faith in Cameron and in the science to get us to the promised land. But let’s not get too excited. PIPE investors came into the deal because they signed a CDA and saw the EIND data before anyone else did. It was clear to everyone involved in the PIPE that as soon as
A) a JPM financing led by Venrock and
B) positive EIND data were announced, that this ticker was worth a whole lot more than $0.87. And they were right. Stock had its 2 best days when the financing was announced and when eIND data was announced.
That’s it. That was the edge. Now that they’re liquid and everything they learned under CDA has been made public, they have no reason to stay in this name except to speculate on whether or not we get positive data moving forward. Expect more selling pressure from PIPE investors. The S1 has only been effective for a week and there are a ton more shares hitting the market.

You’re right. I’m fake. Start being objective and let’s get on the same page eh? We both have the same goals here mate.

I’m a significant retail shareholder, one of the few this company has. I believe we go to $50 on positive efficacy data on either our phase 3 or the BET trial, but literally MWM posts hundreds of times a day so I question his credibility sometimes. That’s all. Also, he referred to me as an idiot. Was I supposed to stay quiet?

You’re a pumper. Probably paid by the company. All good. It’s the cost of doing business while being on the OTC. Like I said, no reason to name call people for doing the prudent thing. Also, everyone that had a look at the deal, whether we were given stock or not, had to be a “Qualified Purchaser”. Look it up, bet you’ve never heard the term.

Someone gets a little sensitive when their favorite stock is down much? Chill dude - everyone here is long, even the PIPE investors that are selling. If you were up 5x, you’d take your principal off too and are lying is you say otherwise. I would guess we’ll see about 10m shares come off the table before we stabilize. It’s the nature of the game. Don’t call people names because they had access to a deal that you couldn’t sniff if you tried.

You don’t know what you are talking about. There are retail names on the S-1, none that we’re invested through Noble. Only Noble investor that got an allocation was an Asian based pharma company for $4m. The other retail investors are affiliates of the company. Don’t speak of what you don’t know. You lose credibility.

I’ll take it. They own over 50% of the company, and I would assume Venrock Et al will recover their cost basis when they’re able to, but the EFFECT notice will get us on NASDAQ and bring in a much larger pool of buyers. Exciting times ahead indeed. Say the $0.87 buyers take 20% off the table, that will increase our public float by about 20m shares and hopefully alleviates our liquidity concerns. Any real efficacy data sends this to $20 overnight.

No, they did not sign a 6 month lock up. Management signed a 6 month lock up, but those shares are liquid once the S1 becomes effective.

I’m back old friends and in at $4.75. Haven’t forgiven Durrant but this is a buy no doubt.

I never intended to come here and bash the stock/company. Only meant to provide commentary on issues the company faces that I have first hand knowledge of. It may have come off the wrong way because on a personal level, it cost me mid 6 figures in paper profit, so of course I was pretty darn upset.
The litigation is one of a host of issues HGEN faces as they race to the finish line, but it doesn’t mean I believe one should steer clear.
If the plaintiffs are ultimately successful, the absolute worst case scenario for HGEN is about 10% dilution. Boohoo.
We all know what a Covid-19 approval is worth. CYDY is expected to announce data in the coming weeks and look what happened there!
2.5 Billion!
That takes HGEN to 10+ on ANTICIPATION of data. I can’t imagine what an approval does to the market cap... $10B, $20B? And they have enough cash in the bank to get to the finish line.
I was enamored at .87, and I love it at $3.
I appreciate the folks here suggesting I become a moderator, but I will respectfully pass. I’m happy reading all of your intelligent commentary and chiming in every once in a while when I think I can provide value.
GLTA.

It refers to the Post effective amendment dated 6/16. That S-1 amendment was to de-register all the non issued Lincoln Park stock (that was registered on 11/20/19). This notice of effect basically declares that amendment effective and the Lincoln Park financing is officially over. Nothing material here, just procedural.

If you like it at $3, you LOVE it at .87!

No conflict. Shareholders sue companies all the time. As soon as there’s an EFFECT statement filed, 82m shares hit the float. That’s worrisome.
Ultimately, however, it’s all about the data. From a risk reward standpoint, this stock can go to either .50c or $20. I’ll take that bet. Nobody knows how the data will read out.
Compassionate use was compelling, but that trial had its flaws.
There are certainly pedigreed people behind this, and the investors in the PIPE make this even more compelling, but no guarantee of success.
The PIPE investors are almost guaranteed to make money because they understand that just news of their investment would send the stock up 300%. Add in the fact that management agreed to a 180 day lock-up on 50% of the company, and they used this financing to retire the very dilutive and toxic Lincoln park financing, and you have a win win win all around for the PIPE investors.
4 billionaires on that selling shareholder list. Frankly, it’s why they are billionaires.

At $0.87 it was a grand slam deal. Basically piggy backing off of JPM and Venrock’s work. You know they don’t lose money.
At this point, it’s really a toss up. Preliminary analysis on phase 3 is incoming. I don’t have a crystal ball and can’t tell you which way it goes, but this is certainly worth a small portion of anyone’s portfolio. If the data is stunning, we’re looking at a potential $20b market cap. If it’s a dud, we’re back to $1. Trade accordingly. Assess your risk tolerance and place your bet.

Agreed. All PIPE investors can sell prior to 180 days, so long as the S1 is declared effective by the SEC. The S1 has been filed, but not yet declared effective. Therefore, no selling.

PIPE investors can’t sell yet. S1 isn’t effective. Maybe they are shorting now to lock in gains prior to effect statement on S1 from SEC.
Also, Insiders etc signed 180 day lock up as part of PIPE. I believe a majority of NOMIS stock is part of that lock-up.

JP Morgan was always in the room.
Look at the stockholders on the S1.
He gave the Noble allocation to friends and family of the fund managers at the 11th hour. Curious to see what shows up in discovery. I wish you all and the company well in a quest to find a real therapeutic for COVID-19. I believe in Lenzilumab and ultimately think they get FDA approval.
It does not change the fact that Cameron is a liar. That is all. He’s the CEO of a public company and should be held to a higher standard. Smaller retail investors were approached with this offering and many saw it as the deal of a lifetime. I heard some even withdrew IRA funds and paid the early penalty because Cameron repeatedly assured them their allocation. The fact are that he took that economic opportunity from investors who are barely accredited and gave it to Billionaires.
Still, this stock should be trading at $10+. Not questioning the company, just Cameron’s character.

Don’t know. I believed I am owed several 100k shares at .87
Compared to CYDY, and they are very similar, this should trade at $10 in my opinion. But my personal experience is that Cameron is an untrustworthy CEO and this ordeal has made me doubt everything he says.
Seriously, he rushed us to get our wires in on Monday, and we found out we were excluded via their press release. Love the science behind Lenzilumab but CD is the wrong guy to be steering this ship.

Volume weighted moving average, not trailing moving average. Barely any volume on Friday May 29 over $1 so that wasn’t changing. We were told all week between 86 and 89. Same thing.

Durant called the guys at Noble on Sat morning and basically said that the deal was oversubscribed and was increasing in size, and indicated that they should work the weekend and make sure wires came in by Tuesday June 2 and 2PM EST. He also told them that he would allocate them $20m as opposed to the initial $10m allocation they were given and had them work all weekend into Monday night to get paperwork and funds in. My broker called me suddenly on Saturday afternoon and told me Cameron upsized the deal and increased Nobles allocation so I doubled down on my investment.

Price was fixed at $0.87. Likely that an affiliate sent the stock up 50% on Friday on almost NO volume to increase demand for the offering. Sounds like further market manipulation to me.

JPM knew all along that we were investing. They had the right to raise $20m externally and hired Noble to do that for them.
Durant used us as a free put option to manipulate demand for the offering. Would not be surprised if several other lawsuits came out of this. Best case scenario, Cameron is a terrible human being. Worst case, a while collar criminal. Let’s see what the courts determine.

$16m worth of investor dollars declined without notice at .87 is worth $100m now. Lawyer costs a lot less.